An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

Inclusion Criteria:

- Histologically or cytologically confirmed Stage IIIb or IV breast cancer with
cutaneous metastases.

Exclusion Criteria:

- Participants receiving any medications or substances that are known to cause
photosensitivity (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea
hypoglycemic agents, thiazide diuretics, griseofulvin, fluoroquinolones, St. Johns'
wort, amiodarone) are ineligible.

- Participants who have received prior systemic therapy (chemotherapy or targeted
therapy) within 7 days of Study Day 1 or those who have not recovered from clinically
significant adverse events due to agents administered more than 7 days earlier.
(continuation of the same regimen of HER-2 antibody targeted therapy agents, hormonal
therapy and treatment with bisphosphonates or denosumab are permitted)

- Participants who are receiving any other investigational agents during the proposed
treatment cycle.